Latest news with #triple-negative
The Independent
09-07-2025
- Health
- The Independent
Breast cancer vaccine breakthrough raises hopes of eradicating disease
A breakthrough breast cancer vaccine has completed Phase one trials, with over 75 percent of participants showing a strong immune response, raising hopes it could help eradicate the disease by 2030. The vaccine, developed by Anixa Biosciences and the Cleveland Clinic, targets alpha‑lactalbumin, a milk protein linked to aggressive triple-negative breast cancer, to help prevent and treat the disease. That form of cancer is known as the most deadly. During the first phase of the trial, 35 women, many with triple-negative breast cancer or a genetic risk, received the vaccine. Blood tests showed that more than 75 percent developed a strong immune response, indicated by antibodies on their white blood cells. That improved response can help a person's immune system identify and destroy cancerous cells. Side effects of the vaccine were limited to mild injection‑site irritation. Dr. Amit Kumar, Anixa's CEO, called the findings 'very exciting' in an interview with the New York Post. 'It's a very new mechanism and we think that if this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we've done for polio and various other infectious diseases,' Kumar told the outlet. Phase two is scheduled for next year and will test a larger group of participants and expand testing to additional types of breast cancer. Unlike vaccines for infections, cancer vaccines face challenges because cancer originates from the body's own cells, making it harder for the immune system to distinguish them. Past attempts often targeted proteins found in both cancerous and healthy tissues, sometimes causing harmful immune responses. Breast cancer cells often contain alpha-lactalbumin, a protein normally only present during pregnancy and breastfeeding. A Cleveland Clinic scientist proposed targeting it in women not planning to have more children 20 years ago, leading to the current vaccine trial. The US Department of Defense funded the study, but future progress may be affected by budget cuts. Researchers plan to present their results to the agency this year.
Yahoo
08-07-2025
- Health
- Yahoo
Breast cancer vaccine breakthrough as more than 75% of women show immune response in new test
A breakthrough breast cancer vaccine has completed Phase one trials, with over 75 percent of participants showing a strong immune response, raising hopes it could help eradicate the disease by 2030. The vaccine, developed by Anixa Biosciences and the Cleveland Clinic, targets alpha‑lactalbumin, a milk protein linked to aggressive triple-negative breast cancer, to help prevent and treat the disease. That form of cancer is known as the most deadly. During the first phase of the trial, 35 women, many with triple-negative breast cancer or a genetic risk, received the vaccine. Blood tests showed that more than 75 percent developed a strong immune response, indicated by antibodies on their white blood cells. That improved response can help a person's immune system identify and destroy cancerous cells. Side effects of the vaccine were limited to mild injection‑site irritation. Dr. Amit Kumar, Anixa's CEO, called the findings 'very exciting' in an interview with the New York Post. 'It's a very new mechanism and we think that if this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we've done for polio and various other infectious diseases,' Kumar told the outlet. Phase two is scheduled for next year and will test a larger group of participants and expand testing to additional types of breast cancer. Unlike vaccines for infections, cancer vaccines face challenges because cancer originates from the body's own cells, making it harder for the immune system to distinguish them. Past attempts often targeted proteins found in both cancerous and healthy tissues, sometimes causing harmful immune responses. Breast cancer cells often contain alpha-lactalbumin, a protein normally only present during pregnancy and breastfeeding. A Cleveland Clinic scientist proposed targeting it in women not planning to have more children 20 years ago, leading to the current vaccine trial. The US Department of Defense funded the study, but future progress may be affected by budget cuts. Researchers plan to present their results to the agency this year.
The Independent
08-07-2025
- Health
- The Independent
Breast cancer breakthrough raises hopes for disease eradication
A breast cancer vaccine has completed phase one trials, showing a strong immune response in over 75 per cent of participants. Developed by Anixa Biosciences and the Cleveland Clinic, the vaccine targets alpha-lactalbumin, a protein linked to aggressive triple-negative breast cancer, aiming to prevent and treat the disease. The trial involved 35 women, many with triple-negative breast cancer or genetic risk, with blood tests confirming a strong antibody response and only mild injection-site irritation. Researchers are hopeful the vaccine could help eradicate breast cancer by 2030, with Anixa's CEO, Dr Amit Kumar, calling the findings 'very exciting'. Phase two trials are scheduled for next year to test a larger group and additional breast cancer types, with the study funded by the US Department of Defence. Breast cancer vaccine breakthrough as more than 75% of women show immune response in new test
The Independent
08-07-2025
- Health
- The Independent
Breast cancer vaccine breakthrough as more than 75% of women show immune response in new test
A breakthrough breast cancer vaccine has completed Phase one trials, with over 75 percent of participants showing a strong immune response, raising hopes it could help eradicate the disease by 2030. The vaccine, developed by Anixa Biosciences and the Cleveland Clinic, targets alpha‑lactalbumin, a milk protein linked to aggressive triple-negative breast cancer, to help prevent and treat the disease. That form of cancer is known as the most deadly. During the first phase of the trial, 35 women, many with triple-negative breast cancer or a genetic risk, received the vaccine. Blood tests showed that more than 75 percent developed a strong immune response, indicated by antibodies on their white blood cells. That improved response can help a person's immune system identify and destroy cancerous cells. Side effects of the vaccine were limited to mild injection‑site irritation. Dr. Amit Kumar, Anixa's CEO, called the findings 'very exciting' in an interview with the New York Post. 'It's a very new mechanism and we think that if this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we've done for polio and various other infectious diseases,' Kumar told the outlet. Phase two is scheduled for next year and will test a larger group of participants and expand testing to additional types of breast cancer. Unlike vaccines for infections, cancer vaccines face challenges because cancer originates from the body's own cells, making it harder for the immune system to distinguish them. Past attempts often targeted proteins found in both cancerous and healthy tissues, sometimes causing harmful immune responses. Breast cancer cells often contain alpha-lactalbumin, a protein normally only present during pregnancy and breastfeeding. A Cleveland Clinic scientist proposed targeting it in women not planning to have more children 20 years ago, leading to the current vaccine trial. The US Department of Defense funded the study, but future progress may be affected by budget cuts. Researchers plan to present their results to the agency this year.
Medscape
24-06-2025
- Health
- Medscape
Early Breast Cancer Highlights From ASCO 2025
Reporting on studies in early breast cancer presented at ASCO 2025, Dr Ian Krop of Yale Cancer Center discusses potential refinements in treatment across all subtypes as well as a significant study in supportive care. Dr Krop begins with the neoCARHP trial, which reevaluated the role of carboplatin, a component of standard neoadjuvant therapy for patients with early HER2-positive breast cancer. Omitting carboplatin yielded comparable pathologic complete response results confirming noninferiority of the carboplatin-free regimen. Carboplatin was also reexamined in the context of triple-negative breast cancer in the phase 3 NRG-BR003 trial. Invasive disease-free survival rates at 5 years were slightly higher among patients taking carboplatin, although patients who had BRCA mutations appeared to experience more benefit. In hormone receptor (HR)-positive disease, Dr Krop discusses 15-year updated data from the SOFT and TEXT trials assessing the benefit of adjuvant exemestane with ovarian function suppression (OFS) vs tamoxifen plus OFS. Results confirmed the benefit of adding OFS and switching to exemestane, particularly for higher-risk patients. Vasomotor symptoms can compromise quality of life for patients with breast cancer and can lead to nonadherence. Dr Krop highlights the OASIS 4 trial, which evaluated elinzanetant in patients with HR-positive disease. Promising results in this trial are helping to move this therapy toward FDA approval.
